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j ourna l homepage: www.e lsev ie r .com/ locate /bbad isEditorialResveratrol: Challenges in translating pre-clinical ﬁndings to improved
patient outcomesIn recent decades, the average life expectancy of humans, particularly
in westernized societies, has been steadily increasing. Better nutrition
and health care are among the factors responsible for the increased
lifespan. However, although life expectancy is increasing, the prevalence
of chronic diseases is also rapidly increasing. For example, obesity is
becoming amajor health problem in a large part of theworld, and coun-
tries with greater than 50% of the adult population being overweight are
becoming the norm. This increase in the prevalence of obesity comes
with a further increase in chronic metabolic diseases, which threatens
the steady increase in life expectancy that we have grown accustomed
to. Therefore, research efforts are shifting towards attempts to prolong
a healthy life by reducing the prevalence of obesity as well as attempts
to develop novel therapies that maintain normal metabolism even in
the presence of obesity. One of these therapies, resveratrol, has been
shown in animal models and in a few clinical studies to have beneﬁt in
patients with metabolic conditions arising from obesity and/or insulin
resistance. In addition, resveratrol also appears to hold promise for the
treatment of many chronic diseases both dependent and independent
of changes in metabolism.
Interest in resveratrol expanded after it was identiﬁed as an active
polyphenol, present in higher amounts in red wine, which could have
cardioprotective by inhibiting platelet aggregation and lowering low-
density lipoprotein levels. Subsequent investigation of the pharmaco-
logical activities of resveratrol revealed that it also has potent antioxi-
dant, anti-carcinogenic and anti-inﬂammatory activities. Furthermore,
in 2003 resveratrol was discovered to be a small molecule activator of
SIRT1, a molecule that has been linked to longevity. In the years that
followed, resveratrol has been extensively studied in cell and animal
studies, in a wide range of diseases. In fact, a PubMed search with ‘res-
veratrol’ as a keyword reveals over 7000 publications, demonstrating
the vast amount of research being conducted in order to describe and
understand the effects of resveratrol. Of importance, resveratrol has
been linked to beneﬁcial effects not only in obesity and energymetabo-
lism, but also in cardiovascular disease, cancer, osteoporosis, neurologi-
cal disorders, Alzheimer's, as well as extending lifespan.
Overall, the results of the pre-clinical studies have been promising
and these ﬁndings have created high expectations for the therapeutichttp://dx.doi.org/10.1016/j.bbadis.2015.02.002
0925-4439/© 2015 Elsevier B.V. All rights reserved.value of resveratrol to treat chronic diseases. However, as is often the
case, the translational steps from cell and animal studies towards
humans has turned out to be less than straightforward. Although the
number of clinical trials with resveratrol is still limited (combining the
PubMed search ‘resveratrol’with ‘clinical trial’ only reveal ~80 publica-
tions— of whichmany are reviews), the number of trials showing ben-
eﬁcial effects may balance the number of trials that failed to show
favourable effects. This then begs the question: does this mark the end
of resveratrol as a promising candidate to improve health in humans?
Before this question can be answered, many other questions need to
be answered ﬁrst. For example, do we know what the optimal dose
and treatment duration for resveratrol is, and have we fully revealed
its exact mechanism(s) of action? Furthermore, it needs to be revealed
for which subjects/patients resveratrol may be beneﬁcial, as it may be
too simpliﬁed to assume that it will improve health in all (patient) pop-
ulations spanning a vast array of conditions. Thus, more well-designed
clinical trials are needed before we can decide whether or not resvera-
trol can meet our high expectations.
The goal of this special issue is to provide detailed reviews of the
existing literature covering a wide breadth of topics and to help address
the challenges associated with translating the pre-clinical data to
humans. As we contemplate the existing ﬁndings, it may be good to
reset the expectations of resveratrol, as it may be unrealistic to consider
resveratrol as a wonder drug that can relieve all negative consequences
of our lifestyle characterized by nutritional overconsumption, physical
inactivity, and other stresses.
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Dr. Schrauwen is investigating if targeting mitochondrial function, among others via
resveratrol, can aid to prevent and treat type 2 diabetes and its related complications.Jason R.B. Dyck
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